These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 30852290

  • 1. Risk of infection with different immunosuppressive drugs combined with glucocorticoids for the treatment of idiopathic membranous nephropathy: A pairwise and network meta-analysis.
    Liu D, Yang Y, Kuang F, Qing S, Hu B, Yu X.
    Int Immunopharmacol; 2019 May; 70():354-361. PubMed ID: 30852290
    [Abstract] [Full Text] [Related]

  • 2. Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis.
    Ren S, Wang Y, Xian L, Toyama T, Jardine M, Li G, Perkovic V, Hong D.
    PLoS One; 2017 May; 12(9):e0184398. PubMed ID: 28898290
    [Abstract] [Full Text] [Related]

  • 3. Comparative efficacy of 13 immunosuppressive agents for idiopathic membranous nephropathy in adults with nephrotic syndrome: a systematic review and network meta-analysis.
    Zheng Q, Yang H, Liu W, Sun W, Zhao Q, Zhang X, Jin H, Sun L.
    BMJ Open; 2019 Sep 11; 9(9):e030919. PubMed ID: 31511292
    [Abstract] [Full Text] [Related]

  • 4. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.
    Chen Y, Schieppati A, Chen X, Cai G, Zamora J, Giuliano GA, Braun N, Perna A.
    Cochrane Database Syst Rev; 2014 Oct 16; 2014(10):CD004293. PubMed ID: 25318831
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis.
    Chen M, Zhang X, Xiong Y, Xu G.
    Int Urol Nephrol; 2023 Mar 16; 55(3):641-651. PubMed ID: 36161550
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and cost of different treatment in patients with idiopathic membranous nephropathy: A network meta-analysis and cost-effectiveness analysis.
    Dai P, Xie W, Yu X, Sun J, Wang S, Kawuki J.
    Int Immunopharmacol; 2021 May 16; 94():107376. PubMed ID: 33582591
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis.
    Lin W, Li HY, Lin S, Zhou T.
    Drug Des Devel Ther; 2019 May 16; 13():2179-2186. PubMed ID: 31308629
    [Abstract] [Full Text] [Related]

  • 8. A comparison of cyclophosphamide versus tacrolimus in terms of treatment effect for idiopathic membranous nephropathy: A meta-analysis.
    Li YC, Huang J, Li X, Zhao SM.
    Nefrologia (Engl Ed); 2019 May 16; 39(3):269-276. PubMed ID: 30755327
    [Abstract] [Full Text] [Related]

  • 9. Tacrolimus versus cyclophosphamide for patients with idiopathic membranous nephropathy and treated with steroids: a systematic review and meta-analysis of randomized controlled trials.
    Huang H, Liang Z, Zheng X, Qing Q, Du X, Tang Z, Wei M, Wang C, Zhong Q, Lin X.
    Ren Fail; 2021 Dec 16; 43(1):840-850. PubMed ID: 34016023
    [Abstract] [Full Text] [Related]

  • 10. Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: a nationwide survey in the Netherlands.
    Hofstra JM, Wetzels JF.
    Nephrol Dial Transplant; 2008 Nov 16; 23(11):3534-8. PubMed ID: 18559961
    [Abstract] [Full Text] [Related]

  • 11. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.
    Schieppati A, Perna A, Zamora J, Giuliano GA, Braun N, Remuzzi G.
    Cochrane Database Syst Rev; 2004 Oct 18; (4):CD004293. PubMed ID: 15495098
    [Abstract] [Full Text] [Related]

  • 12. The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy.
    Liang Q, Li H, Xie X, Qu F, Li X, Chen J.
    Ren Fail; 2017 Nov 18; 39(1):512-518. PubMed ID: 28562168
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of tacrolimus monotherapy versus cyclophosphamide-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis.
    Gong L, Xu M, Xu W, Tang W, Lu J, Jiang W, Xie F, Ding L, Qian X.
    Medicine (Baltimore); 2021 Jul 16; 100(28):e26628. PubMed ID: 34260552
    [Abstract] [Full Text] [Related]

  • 14. Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials.
    Qiu TT, Zhang C, Zhao HW, Zhou JW.
    Autoimmun Rev; 2017 Feb 16; 16(2):136-145. PubMed ID: 27988429
    [Abstract] [Full Text] [Related]

  • 15. Treatment of Idiopathic Membranous Nephropathy for Moderate or Severe Proteinuria: A Systematic Review and Network Meta-Analysis.
    Chen M, Liu J, Xiong Y, Xu G.
    Int J Clin Pract; 2022 Feb 16; 2022():4996239. PubMed ID: 35685506
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis.
    Jiang N, Jin S, Yu C, Zhao J, Wang Q, Tian X, Li M, Zeng X.
    Front Immunol; 2023 Feb 16; 14():1232244. PubMed ID: 37901212
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy.
    Zou H, Jiang F, Xu G.
    Ren Fail; 2019 Nov 16; 41(1):673-681. PubMed ID: 31354007
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of cyclosporine A in the treatment of idiopathic membranous nephropathy in an Asian population.
    Lin S, Li HY, Zhou T, Lin W.
    Drug Des Devel Ther; 2019 Nov 16; 13():2305-2330. PubMed ID: 31371924
    [Abstract] [Full Text] [Related]

  • 19. Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy.
    Peng L, Wei SY, Li LT, He YX, Li B.
    J Formos Med Assoc; 2016 Jan 16; 115(1):11-8. PubMed ID: 26315481
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of Tacrolimus versus Cyclosporine A for Idiopathic Membranous Nephropathy:A Network Meta-analysis.
    Xu P, He YD, Yu ZM, Luo K, Xie HY, Zou PM, Gu X, Wang SR, Cai JF, Xu Q, Li H, Li XW.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Feb 28; 40(1):41-51. PubMed ID: 29532780
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.